По вашему запросу найдено документов: 109

Страница 5 из 11

Оценка эффективности эзофагопротектора в лечении гастроэзофагеальной рефлюксной болезни с экстраэзофагеальной симптоматикой у детей и подростков: результаты открытого наблюдательного многоцентрового исследования
Evaluation of esophagoprotective therapy for gastroesophageal reflux disease with extraesophageal symptoms in children and adolescents: results of an open-label, multicenter, observational study
Шумилов, П.В., Хавкин, А.И., Кучерявый, Ю.А., Андреев, Д.Н., Гильманов, А.A., Васильев, Р.В., Кучина, Е.С., Маринчук, С.А., Назарова, О.В., Сафонова, Н.Г., Степкина, Я.М., Трибунская, С.А., Чикунова, М.В., Шанава, О.А., Shumilov, P.V., Khavkin, A.I., Kucheryavy, Yu.A., Andreev, D.N., Gilmanov, A.A., Vasilyev, R.V., Kuchina, E.S., Marinchuk, S.A., Nazarova, O.V., Safonova, N.G., Stepkina, Ya.M., Tribunskaya, S.A., Chikunova, M.V., Shanava, O.A. (2022)
Evaluation of esophagoprotective therapy for gastroesophageal reflux disease with extraesophageal
Association of a Single-Nucleotide Variant rs11100494 of the NPY5R Gene with Antipsychotic-Induced Metabolic Disorders
Dobrodeeva, V.S., Shnayder, N.A., Novitsky, M.A., Asadullin, A.R., Vaiman, E.E., Petrova, M.M., Limankin, O.V., Neznanov, N.G., Garganeeva, N.P., Nasyrova, R.F. (2022)
weight of more than 6% since the start of APs therapy. Group 2 comprised 74 patients with SSDs taking APs
MicroRNAs as prognostic markers and therapeutic targets in gliomas
Sufianov, A., Begliarzade, S., Ilyasova, T., Liang, Y., Beylerli, O. (2022)
be used for diagnosis and prognosis, including the response of a particular patient to therapy
MicroRNAs-mediated regulation of glucose transporter (GLUT) expression in glioblastoma
Beylerli, Ozal, Sufianova, Galina, Shumadalova, Alina, Zhang, Daming, Gareev, Ilgiz (2022)
the sensitivity of glioblastoma to current therapies. © 2022 The Authors
MicroRNAs as potential diagnostic markers of glial brain tumors
Sufianov, Albert, Begliarzade, Sema, Ilyasova, Tatiana, Xu, Xun, Beylerli, Ozal (2022)
. Glioblastoma (GBM), a grade IV brain tumor, is known for its heterogeneity and resistance to therapy. Modern
ВОЗМОЖНОСТИ ПРИМЕНЕНИЯ ОНЛАЙН-ПЛАТФОРМ AMRMAP И AMRBOOK В ОБРАЗОВАТЕЛЬНОМ ПРОЦЕССЕ НА ЗАНЯТИЯХ ПО ФАКУЛЬТЕТСКОЙ ПЕДИАТРИИ
POSSIBILITIES OF APPLICATION OF AMRMAP AND AMRBOOK ONLINE PLATFORMS IN THE EDUCATIONAL PROCESS AT THE CLASSES OF PEDIATRICS FACULTY
ШАНГАРЕЕВА, З.А, ФАЙЗУЛЛИНА, Р.М., САННИКОВА, А.В., ВИКТОРОВ, В.В., SHANGAREEVA, Z.A., FAYZULLINA, R.M., SANNIKOVA, A.V., VIKTOROV, V.V. (2022)
ЭФФЕКТИВНОСТЬ ИНГИБИТОРА ТИРОЗИНКИНАЗ 1-ГО ПОКОЛЕНИЯ (СУНИТИНИБ) В ТЕРАПИИ МЕТАСТАТИЧЕСКОГО ПОЧЕЧНО-КЛЕТОЧНОГО РАКА В АЛЬТЕРНАТИВНЫХ РЕЖИМАХ ДОЗИРОВАНИЯ
EFFICACY OF THE 1ST GENERATION TYROSINE KINASE INHIBITOR SUNITINIB IN THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN ALTERNATIVE DOSING REGIMENS
МЕНЬШИКОВ, К. В., СУЛТАНБАЕВ, А. В., МУСИН, Ш. И., ИЗМАЙЛОВ, А. A., ЧАЛОВ, В. С., МЕНЬШИКОВА, И. А., СУЛТАНБАЕВА, Н. И., ПОПОВА, Е. В., ЛИПАТОВ, Д. О., MENSHIKOV, K. V., SULTANBAEV, A. V., MUSIN, SH. I., IZMAILOV, A. A., CHALOV, V. S., MENSHIKOVA, I. A., SULTANBAEVA, N. I., POPOVA, E. V., LIPATOV, D. O. (2022)
Genetic Predisposition to Schizophrenia and Depressive Disorder Comorbidity
Shnayder, N.A., Novitsky, M.A., Neznanov, N.G., Limankin, O.V., Asadullin, A.R., Petrov, A.V., Dmitrenko, D.V., Narodova, E.A., Popenko, N.V., Nasyrova, R.F. (2022)
and clinical predictors and a personalized therapy strategy for schizophrenia. However, it should be recognized
Genetic Biomarkers of Antipsychotic-Induced Prolongation of the QT Interval in Patients with Schizophrenia
Vaiman, E.E., Shnayder, N.A., Zhuravlev, N.M., Petrova, M.M., Asadullin, A.R., Al-Zamil, M., Garganeeva, N.R., Shipulin, G.A., Cumming, G., Nasyrova, R.F. (2022)
of which is influenced by modifying factors (APs’ dose, duration of APs therapy, APs polytherapy
Role of retroelements in the development of COVID-19 neurological consequences
Mustafin, Rustam N., Kazantseva, Anastasiya V, Kovas, Yulia V, Khusnutdinova, Elza K (2022)
for developing targeted therapy for neurological consequences of COVID-19 using miRNAs, since epigenetic changes

Страница 5 из 11

Google Scholar
OpenDoar

Фасеты

Авторы
Ключевые слова
Год